Two High-Performance Materials from Samyang Group Newly Selected as "World-Class Products"

MPC Derivatives and Absorbable Hemostat Technologies Recognized
Samyang KCI and Samyang Biopharm Secure Global Market Potential
High Prospects for Export Growth... "Aiming for Global Advancement"

Two high-performance materials from Samyang Group have been newly listed as "World-Class Products," as designated by the Ministry of Trade, Industry and Energy.

Samyang Biopharm and Samyang KCI announced on the 19th that they each received certification for next-generation and current world-class products, respectively, at the "2025 World-Class Product Certification Ceremony" held on the 18th at Lotte Hotel Jamsil in Songpa-gu, Seoul. World-class products are divided into current and next-generation categories based on export volume and global market share. Products that export more than 5 million dollars (approximately 7.3 billion won) annually, hold a global market share of at least 5%, and rank within the top five worldwide are designated as "current world-class products." Items that are expected to enter the global top five within the next seven years are designated as "next-generation world-class products."

Samyang Biopharm and Samyang KCI each received certification for next-generation and current world-class products, respectively, at the "2025 World-Class Product Certification Ceremony" held on the 18th at Lotte Hotel Jamsil in Songpa-gu, Seoul. Samyang Group

Samyang KCI's "MPC (Methacryloyloxyethyl Phosphorylcholine) Derivatives," selected as a current world-class product, are high-performance materials that mimic the phospholipid structure of human cell membranes. They are particularly effective in strengthening the skin barrier and maintaining moisture. Thanks to their biocompatibility and low-irritation properties, they are widely used in high-moisturizing skincare and sunscreens. Samyang KCI is recognized for its competitiveness as the only domestic company possessing both MPC raw material manufacturing and derivative technology.

Samyang Biopharm's "SurgiGuard," designated as a next-generation world-class product, is an absorbable hemostat developed with proprietary technology. It uses a biocompatible material that safely decomposes in the body, making it suitable for various surgical fields such as general surgery, obstetrics and gynecology, and orthopedics. In December last year, it obtained "CE MDR" certification, the European medical device safety regulation.

Ahn Taehwan, Chief Operating Officer of Samyang KCI, stated, "Our technological capabilities and development competence have been recognized in the global market," adding, "We will accelerate research and development to expand the scope of application to medical supplies."

Meanwhile, Samyang Biopharm's absorbable suture thread was selected as a world-class product in 2019, and Samyang KCI's two hair care materials were selected in 2006 and 2014, respectively.

This content was produced with the assistance of AI translation services.